XOFIGO Drug Patent Profile
✉ Email this page to a colleague
When do Xofigo patents expire, and what generic alternatives are available?
Xofigo is a drug marketed by Bayer Hlthcare and is included in one NDA.
The generic ingredient in XOFIGO is radium ra-223 dichloride. One supplier is listed for this compound. Additional details are available on the radium ra-223 dichloride profile page.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for XOFIGO?
- What are the global sales for XOFIGO?
- What is Average Wholesale Price for XOFIGO?
Summary for XOFIGO
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 1 |
| Finished Product Suppliers / Packagers: | 1 |
| Clinical Trials: | 30 |
| Drug Prices: | Drug price information for XOFIGO |
| What excipients (inactive ingredients) are in XOFIGO? | XOFIGO excipients list |
| DailyMed Link: | XOFIGO at DailyMed |
Recent Clinical Trials for XOFIGO
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| GenesisCare USA | Phase 3 |
| Bayer | Phase 4 |
| Tulane University | Phase 3 |
Pharmacology for XOFIGO
| Drug Class | Radioactive alpha-Particle Emitting Therapeutic Agent |
| Mechanism of Action | alpha-Particle Emitting Activity |
US Patents and Regulatory Information for XOFIGO
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Bayer Hlthcare | XOFIGO | radium ra-223 dichloride | SOLUTION;INTRAVENOUS | 203971-001 | May 15, 2013 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for XOFIGO
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Bayer Hlthcare | XOFIGO | radium ra-223 dichloride | SOLUTION;INTRAVENOUS | 203971-001 | May 15, 2013 | ⤷ Sign Up | ⤷ Sign Up |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
International Patents for XOFIGO
See the table below for patents covering XOFIGO around the world.
| Country | Patent Number | Title | Estimated Expiration |
|---|---|---|---|
| Australia | 1700400 | ⤷ Sign Up | |
| New Zealand | 534618 | The preparation and use of radium-223 to target calcified tissues for pain palliation, bone cancer therapy, and bone surface conditioning | ⤷ Sign Up |
| New Zealand | 513135 | The preparation and use of radium-223 to target calcified tissues for pain palliation, bone cancer therapy, and bone surface conditioning | ⤷ Sign Up |
| Germany | 69932183 | ⤷ Sign Up | |
| Spain | 2268888 | ⤷ Sign Up | |
| China | 1194764 | ⤷ Sign Up | |
| >Country | >Patent Number | >Title | >Estimated Expiration |
Supplementary Protection Certificates for XOFIGO
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 1140212 | CA 2014 00027 | Denmark | ⤷ Sign Up | PRODUCT NAME: RADIUM-223 OG OPLOESELIGE SALTE DERAF, HERUNDER RADIUM-223 DICHLORID; REG. NO/DATE: EU/1/13/873 20131113 |
| 1140212 | 507 | Finland | ⤷ Sign Up | |
| 1140212 | C01140212/01 | Switzerland | ⤷ Sign Up | PRODUCT NAME: RADIUM RA-223; REGISTRATION NO/DATE: SWISSMEDIC 62732 29.08.2014 |
| 1140212 | 14C0038 | France | ⤷ Sign Up | PRODUCT NAME: RADIUM 223 AINSI QUE SES SELS PHARMACEUTIQUEMENT ACCEPTABLES,EN PARTICULIER LE DICHLORURE DE RADIUM 223; REGISTRATION NO/DATE: EU/1/13/873 20131113 |
| 1140212 | CR 2014 00027 | Denmark | ⤷ Sign Up | PRODUCT NAME: RADIUM-223 OG OPLOESELIGE SALTE DERAF, HERUNDER RADIUM-223 DICHLORID; REG. NO/DATE: EU/1/13/873 20131113 |
| 1140212 | C300666 | Netherlands | ⤷ Sign Up | PRODUCT NAME: RADIUM-223, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH; REGISTRATION NO/DATE: EU/1/13/873/001 20131113 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2024 - 2025
NCE-1 Patent Challenge Dates 2024 - 2025
Trigger-based marketing for the life sciences
Get DrugPatentWatch Business Intelligence Reports at Amazon.com
DrugChatter - AI-based answers to questions about drugs
RxJam - Digital Marketing for Life Sciences
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2024, www.DrugPatentWatch.com.
See Primary Research Papers Citing DrugPatentWatch
Follow DrugPatentWatch:
